Do analysts recommend INM or LEXX?

Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 76.19%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer INM or LPCN?

Lipocine has a consensus target price of $15.00, indicating a potential upside of 538.30%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer ZIVO or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer INM or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 5,163.16%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend INM or SCNX?

Scienture has a consensus price target of $1.50, indicating a potential upside of 304.31%. Given Scienture's stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

InMed Pharmaceuticals (INM) Competitors

$1.39 +0.04 (+2.67%)

As of 12:20 PM Eastern

Compare

INM vs. LEXX, LPCN, ZIVO, MDCX, and SCNX

Should you buy InMed Pharmaceuticals stock or one of its competitors? InMed Pharmaceuticals's main competitors and comparable companies include Lexaria Bioscience (LEXX), Lipocine (LPCN), ZIVO Bioscience (ZIVO), Medicus Pharma (MDCX), and Scienture (SCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InMed Pharmaceuticals compare to Lexaria Bioscience?

InMed Pharmaceuticals (NASDAQ:INM) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

In the previous week, Lexaria Bioscience had 2 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Lexaria Bioscience and 0 mentions for InMed Pharmaceuticals. Lexaria Bioscience's average media sentiment score of 0.20 beat InMed Pharmaceuticals' score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Lexaria Bioscience	Neutral

InMed Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.93	-$8.16M	-$2.89	N/A
Lexaria Bioscience	$710K	29.68	-$11.90M	-$5.10	N/A

Lexaria Bioscience has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Lexaria Bioscience	N/A	-174.93%	-143.89%

InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 76.19%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

InMed Pharmaceuticals and Lexaria Bioscience tied by winning 8 of the 16 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Lipocine?

InMed Pharmaceuticals (NASDAQ:INM) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Lipocine had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for InMed Pharmaceuticals. Lipocine's average media sentiment score of 0.75 beat InMed Pharmaceuticals' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Lipocine	Positive

InMed Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lipocine has a consensus target price of $15.00, indicating a potential upside of 538.30%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

InMed Pharmaceuticals has a net margin of -132.87% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Lipocine	-755.39%	-64.75%	-57.62%

InMed Pharmaceuticals has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.93	-$8.16M	-$2.89	N/A
Lipocine	$1.57M	12.34	-$9.63M	-$1.79	N/A

Summary

Lipocine beats InMed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

ZIVO Bioscience has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. ZIVO Bioscience's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

ZIVO Bioscience has higher earnings, but lower revenue than InMed Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,045.11	-$7.78M	-$1.40	N/A
InMed Pharmaceuticals	$4.94M	0.93	-$8.16M	-$2.89	N/A

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ZIVO Bioscience has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
InMed Pharmaceuticals	Neutral

Summary

ZIVO Bioscience and InMed Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Medicus Pharma?

InMed Pharmaceuticals (NASDAQ:INM) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Medicus Pharma'saverage media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Medicus Pharma	Neutral

Medicus Pharma has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Medicus Pharma	N/A	-3,137.84%	-263.24%

InMed Pharmaceuticals has higher revenue and earnings than Medicus Pharma. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.93	-$8.16M	-$2.89	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 5,163.16%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

20.1% of InMed Pharmaceuticals shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Medicus Pharma beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Scienture?

InMed Pharmaceuticals (NASDAQ:INM) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 21.4% of Scienture shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Scienture'saverage media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Scienture	Neutral

Scienture has a consensus price target of $1.50, indicating a potential upside of 304.31%. Given Scienture's stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMed Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Scienture has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market.

InMed Pharmaceuticals has higher revenue and earnings than Scienture. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.93	-$8.16M	-$2.89	N/A
Scienture	$430K	35.43	-$41.51M	-$2.10	N/A

Scienture has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Scienture's return on equity of -53.51% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Scienture	N/A	-53.51%	-42.47%

Summary

Scienture beats InMed Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.66M	$12.29B	$7.26B	$12.90B
Dividend Yield	N/A	2.60%	2.53%	8.56%
P/E Ratio	-0.49	789.76	273.76	25.42
Price / Sales	0.93	958.35	679.75	124.45
Price / Cash	N/A	92.66	76.98	52.08
Price / Book	0.21	12.31	12.91	6.15
Net Income	-$8.16M	$2.83B	$3.48B	$349.24M
7 Day Performance	-3.08%	2.37%	-0.18%	-1.39%
1 Month Performance	-5.07%	5.17%	6.63%	2.55%
1 Year Performance	-34.31%	9.58%	25.25%	15.80%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	1.3137 of 5 stars	$1.40 +3.7%	N/A	-37.5%	$4.63M	$4.94M	N/A	10
LEXX Lexaria Bioscience	2.4096 of 5 stars	$11.22 -3.3%	$22.50 +100.5%	-0.7%	$18.51M	$710K	N/A	7
LPCN Lipocine	2.607 of 5 stars	$2.22 +3.3%	$15.00 +575.7%	-18.6%	$18.29M	$1.98M	N/A	10	Gap Up
ZIVO ZIVO Bioscience	N/A	$4.27 flat	N/A	-77.4%	$18.00M	$15.85K	N/A	10
MDCX Medicus Pharma	2.4946 of 5 stars	$0.26 +0.3%	$9.00 +3,337.7%	-87.5%	$16.54M	N/A	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. LEXX, LPCN, ZIVO, MDCX, and SCNX

How does InMed Pharmaceuticals compare to Lexaria Bioscience?

Summary

How does InMed Pharmaceuticals compare to Lipocine?

Summary

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

Summary

How does InMed Pharmaceuticals compare to Medicus Pharma?

Summary

How does InMed Pharmaceuticals compare to Scienture?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. LEXX, LPCN, ZIVO, MDCX, and SCNX

How does InMed Pharmaceuticals compare to Lexaria Bioscience?

Does the media refer more to INM or LEXX?

Which has stronger earnings & valuation, INM or LEXX?

Is INM or LEXX more profitable?

Which has more volatility and risk, INM or LEXX?

Do analysts recommend INM or LEXX?

Do institutionals and insiders have more ownership in INM or LEXX?

Summary

How does InMed Pharmaceuticals compare to Lipocine?

Does the media favor INM or LPCN?

Which has more risk and volatility, INM or LPCN?

Do institutionals and insiders believe in INM or LPCN?

Do analysts prefer INM or LPCN?

Is INM or LPCN more profitable?

Which has better valuation & earnings, INM or LPCN?

Summary

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

Is ZIVO or INM more profitable?

Which has stronger earnings & valuation, ZIVO or INM?

Do insiders & institutionals have more ownership in ZIVO or INM?

Do analysts prefer ZIVO or INM?

Which has more volatility & risk, ZIVO or INM?

Does the media refer more to ZIVO or INM?

Summary

How does InMed Pharmaceuticals compare to Medicus Pharma?

Does the media prefer INM or MDCX?

Is INM or MDCX more profitable?

Which has better valuation & earnings, INM or MDCX?

Which has more risk and volatility, INM or MDCX?

Do analysts prefer INM or MDCX?

Do insiders & institutionals have more ownership in INM or MDCX?

Summary

How does InMed Pharmaceuticals compare to Scienture?

Do insiders and institutionals believe in INM or SCNX?

Does the media favor INM or SCNX?

Do analysts recommend INM or SCNX?

Which has more risk and volatility, INM or SCNX?

Which has better earnings and valuation, INM or SCNX?

Is INM or SCNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools